Author(s): Yu- P. Luong, Robert B. Perni, Yunyi Wei, John H. Van Drie, Roger D. Tung, John A. Thomson, Wayne C. Schairer, B. G. Rao, Janos Pitlik, John P. Maxwell, Luc J. Farmer, Chao Lin, Kai Lin, Scott L. Harbeson, Cynthia A. Gates, David D. Deininger, Lawrence F. Courtney, John J. Court, Kevin M. Cottrell and Shawn D. Britt
Page: [497 - 502] Pages: 6
* (Excluding Mailing and Handling)
A series of novel bicyclic proline P2 scaffold based tetrapeptide inhibitors were designed and prepared. Given their relatively small size, these compounds exhibited exceptional binding affinities and good cellular potencies for HCV protease. One of the best analogues, tricyclic based P2 scaffold 12, had an affinity for HCV with a Ki of 37 nM and cell activity IC50 of 200 nM.
Keywords: Hepatitis C, NS3, •, 4A protease, tetrapeptide inhibitors, VX-950, bicyclic proline, P2 scaffolds
Download PDF Flyer